Breaking News

Canyon Labs Acquires iuvo BioScience’s Lab Services and Consulting Biz

Expands development services for growth in ophthalmic clinical research.

Canyon Labs, a global provider of analytical and packaging lab testing and consulting for medical devices and pharmaceuticals, and iuvo BioScience, a full service provider of ophthalmic medical device and pharmaceutical clinical research services, entered a strategic acquisition that transfers iuvo’s respected lab services and scientific consulting divisions to Canyon Labs.

The transaction positions Canyon Labs to provide comprehensive services in pharmaceutical and medical device development and strengthens iuvo BioScience’s focus on ophthalmic clinical development contract research. The transition includes the full integration of iuvo’s laboratory and consulting personnel into Canyon Labs’ operations, while iuvo BioScience retains its clinical research team and leadership structure.

Canyon Labs operates from three locations: Salt Lake City, UT (headquarters), San Diego, CA, and Rochester, NY. The addition of the Rochester site significantly enhances Canyon Labs’ capabilities with advanced services in rapid sterility, in vitro and in vivo biocompatibility testing, microbiology, and analytical chemistry.

“This acquisition marks a significant milestone in the growth of Canyon Labs’ capacity and capabilities,” said Sarah Ptach, President of Canyon Labs. “By strategically aligning our organizations, we are delivering immediate value to our global client base through faster lead times, expanded capacities, and unparalleled expertise at every step of the process. This integration strengthens our commitment to raising the standard of service in outsourced testing and consulting for the healthcare industry.”

“This transaction marks a defining moment for iuvo,” said Ben Burton, President and CEO of iuvo BioScience. “This strategic decision reinforces our fundamental mission of accelerating patient access to breakthrough vision care treatments. By sharpening our focus on our ophthalmic clinical contract research business, we’re strengthening our ability to provide the high touch, science-driven solutions our customers and partners have come to expect from iuvo.”

The announcement follows iuvo BioScience’s strategic acquisition of Promedica International, a California Corporation (PMI), a specialized ophthalmology contract research organization, in early 2024.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters